Key Points
- David Chang, CEO of Allogene Therapeutics, sold 47,763 shares on March 16 at an average price of $2.47 for about $117,975, trimming his stake by 0.92 to 5,150,599 shares valued near $12.72M.
- ALLO stock traded down to $2.13 (-1.2%) with light volume (115,086 vs. a ~5.58M average), a market cap of roughly $518M, and a 52‑week range of $0.86–$2.80.
- Allogene beat quarterly EPS estimates (‑$0.17 vs. consensus ‑$0.25) and carries a consensus rating of "Moderate Buy" with an average analyst price target of $8.56.
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Benjamin Machinas Beneski sold 4,835 shares of the firm's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $2.47, for a total value of $11,942.45. Following the completion of the transaction, the senior vice president owned 198,205 shares of the company's stock, valued at approximately $489,566.35. The trade was a 2.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Benjamin Machinas Beneski also recently made the following trade(s):
- On Monday, March 2nd, Benjamin Machinas Beneski sold 7,132 shares of Allogene Therapeutics stock. The shares were sold at an average price of $2.60, for a total value of $18,543.20.
- On Monday, February 2nd, Benjamin Machinas Beneski sold 7,549 shares of Allogene Therapeutics stock. The shares were sold at an average price of $1.73, for a total value of $13,059.77.
Allogene Therapeutics Price Performance
NASDAQ:ALLO traded down $0.03 during trading hours on Thursday, reaching $2.13. The company had a trading volume of 322,956 shares, compared to its average volume of 5,583,139. The business's 50 day moving average price is $1.99 and its 200-day moving average price is $1.53. The firm has a market cap of $518.03 million, a PE ratio of -2.44 and a beta of 0.50. Allogene Therapeutics, Inc. has a 1-year low of $0.86 and a 1-year high of $2.80.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its earnings results on Thursday, March 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.08. On average, analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the company. Citizens Jmp raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a report on Friday, January 9th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $14.00 price target on shares of Allogene Therapeutics in a report on Friday, March 13th. Piper Sandler upped their price objective on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the company an "overweight" rating in a report on Friday, March 13th. UBS Group began coverage on Allogene Therapeutics in a research report on Wednesday, January 7th. They issued a "buy" rating and a $8.00 price objective for the company. Finally, Citigroup raised shares of Allogene Therapeutics from a "market perform" rating to an "outperform" rating in a research note on Friday, January 9th. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.56.
View Our Latest Research Report on ALLO
Institutional Investors Weigh In On Allogene Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Mercer Global Advisors Inc. ADV raised its stake in Allogene Therapeutics by 23.0% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 29,512 shares of the company's stock valued at $40,000 after buying an additional 5,514 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of Allogene Therapeutics by 27.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 39,730 shares of the company's stock worth $50,000 after acquiring an additional 8,519 shares in the last quarter. Quadrature Capital Ltd increased its holdings in shares of Allogene Therapeutics by 29.6% in the 2nd quarter. Quadrature Capital Ltd now owns 44,050 shares of the company's stock valued at $50,000 after acquiring an additional 10,059 shares during the last quarter. Brighton Jones LLC increased its holdings in shares of Allogene Therapeutics by 81.6% in the 3rd quarter. Brighton Jones LLC now owns 25,168 shares of the company's stock valued at $31,000 after acquiring an additional 11,311 shares during the last quarter. Finally, Zacks Investment Management raised its position in shares of Allogene Therapeutics by 2.7% during the 3rd quarter. Zacks Investment Management now owns 526,132 shares of the company's stock worth $652,000 after acquiring an additional 13,831 shares in the last quarter. 83.63% of the stock is currently owned by institutional investors and hedge funds.
About Allogene Therapeutics
(
Get Free Report)
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.
The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
